Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance. (7th March 2022)

• Record Type: Journal Article
• Authors: Walter, Justin D; Scherer, Melanie; Hutter, Cedric A J; Garaeva, Alisa A; Zimmermann, Iwan; Wyss, Marianne; Rheinberger, Jan; Ruedin, Yelena; Earp, Jennifer C; Egloff, Pascal; Sorgenfrei, Michèle; Hürlimann, Lea M; Gonda, Imre; Meier, Gianmarco; Remm, Sille; Thavarasah, Sujani; van Geest, Geert; Bruggmann, Rémy; Zimmer, Gert; Slotboom, Dirk J; Paulino, Cristina; Plattet, Philippe; Seeger, Markus A
• Is Part Of: EMBO reports. Volume 23:Number 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-07
• Subjects: escape mutants -- SARS‐CoV‐2 -- sybodies -- synthetic nanobodies -- variants of concern; Molecular biology -- Periodicals; Molecular Biology -- Periodicals; Molecular biology; Periodicals; 572.8
• DOI: 10.15252/embr.202154199
• Languages: English
• ISSNs: 1469-221X

Abstract

Abstract: The ongoing COVID‐19 pandemic represents an unprecedented global health crisis. Here, we report the identification of a synthetic nanobody (sybody) pair, Sb#15 and Sb#68, that can bind simultaneously to the SARS‐CoV‐2 spike RBD and efficiently neutralize pseudotyped and live viruses by interfering with ACE2 interaction. Cryo‐EM confirms that Sb#15 and Sb#68 engage two spatially discrete epitopes, influencing rational design of bispecific and tri‐bispecific fusion constructs that exhibit up to 100‐ and 1, 000‐fold increase in neutralization potency, respectively. Cryo‐EM of the sybody‐spike complex additionally reveals a novel up‐out RBD conformation. While resistant viruses emerge rapidly in the presence of single binders, no escape variants are observed in the presence of the bispecific sybody. The multivalent bispecific constructs further increase the neutralization potency against globally circulating SARS‐CoV‐2 variants of concern. Our study illustrates the power of multivalency and biparatopic nanobody fusions for the potential development of therapeutic strategies that mitigate the emergence of new SARS‐CoV‐2 escape mutants. Synopsis: Sybodies Sb#15 and Sb#68 inhibit SARS‐CoV‐2 infectivity by targeting non‐overlapping epitopes on the spike glycoprotein. Covalent sybody fusion and valency engineering enhances neutralization potency against variants and impedes emergence of escape mutants. Two synthetic nanobodies were in vitro selected against the SARS‐CoV‐2 receptor‐binding domain (RBD). Sb#15 and Sb#68 neutralize viral infection by blocking ACE2 association with the SARS‐CoV‐2 spike protein. Sb#15 and Sb#68 bind to distinct epitopes and promote a unique up/out conformation of the RBD. Sybody fusions increase neutralization potency and attenuate the emergence of novel escape mutants. Abstract : Sybodies Sb#15 and Sb#68 inhibit SARS‐CoV‐2 infectivity by targeting non‐overlapping epitopes on the spike glycoprotein. Covalent sybody fusion and valency engineering enhances neutralization potency against variants and impedes emergence of escape mutants.